With numerous next-generation conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.
21-23 February 2023